A Multiple-Ascending-Dose Study of MK-1708 in Healthy Participants

2024-511405-27-00 Protocol MK-1708-002 Human pharmacology (Phase I) - Other Ended

Start 8 May 2024 · End 17 Sep 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol MK-1708-002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 32
Countries 1
Sites 1

Amyotrophic lateral sclerosis and Alzheimer’s disease

Key facts

Sponsor
Merck Sharp & Dohme LLC
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
8 May 2024 → 17 Sep 2024
Decision date (initial)
2024-04-29
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-511405-27-00
WHO UTN
U1111-1303-6195

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Amyotrophic lateral sclerosis and Alzheimer’s disease

VersionLevelCodeTermSystem organ class
21.1 PT 10002026 Amyotrophic lateral sclerosis 100000004852
20.0 LLT 10001896 Alzheimer's disease 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Merck Sharp & Dohme LLC

Sponsor organisation
Merck Sharp & Dohme LLC
Address
126 East Lincoln Avenue, P. O. Box 2000 P. O. Box 2000
City
Rahway
Postcode
07065-4607
Country
United States

Scientific contact point

Organisation
Merck Sharp & Dohme LLC
Contact name
Zoi Alexopoulou

Public contact point

Organisation
Merck Sharp & Dohme LLC
Contact name
Zoi Alexopoulou

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 32 1
Rest of world 0

Investigational sites

Belgium

1 site · Ended
SGS Belgium
SGS Clinical Pharmacology Unit, Drie Eikenstraat 655, 2650, Edegem

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2024-05-08 2024-09-16 2024-05-10 2024-09-10

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-03-15 Belgium Acceptable
2024-04-29
2024-04-29
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-08-30 Belgium Acceptable
2024-04-29
2024-08-30